User login
Key clinical point: Guselkumab led to early reduction of inflammatory cytokines, which was sustained through 48 weeks, with subsequent improvements in clinical response in patients with active psoriatic arthritis (PsA) and an inadequate response to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: Serum levels of interleukin (IL)-17A, IL-17F, IL-22, and serum amyloid A reduced significantly by week 4 and were sustained through week 48 in the guselkumab (P < .05) vs placebo group when compared with control individuals without PsA. Patients who achieved a clinical response to guselkumab at week 24 showed significant reduction in IL-6 levels at week 4 compared with non-responders (P < .05).
Study details: Findings are from the phase 3b COSMOS study including patients with active PsA and TNFi-IR who were randomly assigned to receive either guselkumab (n = 189) or placebo (n = 96) and compared with matched control individuals.
Disclosures: This study was sponsored by Janssen Research & Development (R&D), LLC, USA. Seven authors declared being employees of Janssen R&D, LLC, or others or owning stocks or stock options in Johnson & Johnson. Several authors declared ties with various sources, including Janssen.
Source: Schett G et al. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: Results from the COSMOS phase 3b study. Arthritis Res Ther. 2023;25:150 (Aug 16, corrected Sep 15). doi: 10.1186/s13075-023-03125-4
Key clinical point: Guselkumab led to early reduction of inflammatory cytokines, which was sustained through 48 weeks, with subsequent improvements in clinical response in patients with active psoriatic arthritis (PsA) and an inadequate response to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: Serum levels of interleukin (IL)-17A, IL-17F, IL-22, and serum amyloid A reduced significantly by week 4 and were sustained through week 48 in the guselkumab (P < .05) vs placebo group when compared with control individuals without PsA. Patients who achieved a clinical response to guselkumab at week 24 showed significant reduction in IL-6 levels at week 4 compared with non-responders (P < .05).
Study details: Findings are from the phase 3b COSMOS study including patients with active PsA and TNFi-IR who were randomly assigned to receive either guselkumab (n = 189) or placebo (n = 96) and compared with matched control individuals.
Disclosures: This study was sponsored by Janssen Research & Development (R&D), LLC, USA. Seven authors declared being employees of Janssen R&D, LLC, or others or owning stocks or stock options in Johnson & Johnson. Several authors declared ties with various sources, including Janssen.
Source: Schett G et al. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: Results from the COSMOS phase 3b study. Arthritis Res Ther. 2023;25:150 (Aug 16, corrected Sep 15). doi: 10.1186/s13075-023-03125-4
Key clinical point: Guselkumab led to early reduction of inflammatory cytokines, which was sustained through 48 weeks, with subsequent improvements in clinical response in patients with active psoriatic arthritis (PsA) and an inadequate response to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: Serum levels of interleukin (IL)-17A, IL-17F, IL-22, and serum amyloid A reduced significantly by week 4 and were sustained through week 48 in the guselkumab (P < .05) vs placebo group when compared with control individuals without PsA. Patients who achieved a clinical response to guselkumab at week 24 showed significant reduction in IL-6 levels at week 4 compared with non-responders (P < .05).
Study details: Findings are from the phase 3b COSMOS study including patients with active PsA and TNFi-IR who were randomly assigned to receive either guselkumab (n = 189) or placebo (n = 96) and compared with matched control individuals.
Disclosures: This study was sponsored by Janssen Research & Development (R&D), LLC, USA. Seven authors declared being employees of Janssen R&D, LLC, or others or owning stocks or stock options in Johnson & Johnson. Several authors declared ties with various sources, including Janssen.
Source: Schett G et al. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: Results from the COSMOS phase 3b study. Arthritis Res Ther. 2023;25:150 (Aug 16, corrected Sep 15). doi: 10.1186/s13075-023-03125-4